| Literature DB >> 17690922 |
Ti-Sun Kim1, Aniela Schenk, Diana Lungeanu, Peter Reitmeir, Peter Eickholz.
Abstract
The purpose of this study was to compare the effect of tooth related and patient related factors on the success of non-surgical and surgical periodontal therapy. In 41 patients (22 female) with untreated and/or recurrent periodontitis, no therapy, scaling and root planing (SRP), or access flap (AF) were assigned according to probing pocket depth (PPD). PPD and vertical relative attachment level (RAL-V) were obtained initially, 3 and 6 months after therapy. Baseline data were compared according to therapy, jaw, tooth type, and site. Factors influencing clinical parameters were identified using multilevel analyses. Baseline PPDs were deeper interproximally, in the maxilla and at premolars compared to buccal/oral sites, mandibular, and anterior teeth. At 6 months, PPD reduction and RAL-V gain were significantly greater at sites receiving SRP and AF as compared to untreated sites (p < 0.001). PPD reduction and RAL-V gain were significantly less (p < 0.005) in smokers as compared to nosmokers and at interproximal sites (p < 0.0001) as compared to buccal/oral sites. RAL-V gain was less in aggressive periodontitis, and PPD reduction was less in the maxilla (p < 0.001). In sites with greater bone loss and infrabony defects, a poorer response was observed regarding RAL-V gain or PPD reduction, respectively. The conclusions of the study are the following: (1) Nonsurgical and surgical periodontal therapies are effective in single-rooted teeth; (2) severe interproximal bone loss and infrabony defects deteriorate clinical results; and (3) there seem to be more defect-associated (tooth, site) factors influencing treatment outcome than patient-associated factors.Entities:
Mesh:
Year: 2007 PMID: 17690922 PMCID: PMC2134843 DOI: 10.1007/s00784-007-0144-x
Source DB: PubMed Journal: Clin Oral Investig ISSN: 1432-6981 Impact factor: 3.573
Clinical parameters at baseline as related to therapy (mean ± standard deviation)
| Sites | No therapy | SRP | AF | |||
|---|---|---|---|---|---|---|
| 1,440 | Range | 2,478 | Range | 198 | Range | |
| RAL-V/mm | 4.35 ± 1.82* | 1.25–19.00 | 5.55 ± 2.30 | 1.75–18.00 | 5.39 ± 2.02 | 2.25–12.00 |
| PPD/mm | 2.45 ± 1.13* | 0.25–2.75 | 3.66 ± 1.98 | 0.50–12.25 | 3.98 ± 2.02 | 1.00–10.50 |
| GI | 0.48 ± 0.84* | 0.94 ± 1.00 | 1.02 ± 0.98 | |||
| PlI | 0.15 ± 0.49 | 0.16 ± 0.53 | 0.14 ± 0.49 | |||
SRP Scaling and root planning, AF access flap
*Statistically significantly different from SRP and AF with p < 0.001
Study population as related to age, sex, smoking habit, and diagnosis
| Variable | Number ( | Percent | |
|---|---|---|---|
| Age | 45.9 ± 10.9 | ||
| Sex | Female | 22 | 53.7 |
| Smoking | Active | 19 | 46.3 |
| Former | 12 | 29.3 | |
| Never | 10 | 24.4 | |
| Diagnosis | Aggressive | 8 | 19.5 |
Intraexaminer reproducibility at baseline, 3, and 6 months examination
| Examination | Measurements ( | ||
|---|---|---|---|
| Baseline | 8,400 | 0.49 | 0.49 |
| 3 months | 8,376 | 0.44 | 0.39 |
| 6 months | 8,292 | 0.53 | 0.39 |
s Standard deviations of a single measurement
Clinical parameters at baseline, 3 and 6 months after therapy (mean ± standard deviation)
| Baseline | 3 months | 6 months | |
|---|---|---|---|
| Sites | 4,146 | 4,146 | 4,146 |
| RAL-V (mm) | 5.12 ± 2.20 | 4.87 ± 1.87 | 4.92 ± 1.84 |
| PPD (mm) | 3.25 ± 1.83 | 2.67 ± 1.19 | 2.67 ± 1.20 |
| GI | 0.78 ± 0.97 | 0.51 ± 0.86 | 0.51 ± 0.86 |
| PlI | 0.16 ± 0.51 | 0.32 ± 0.70 | 0.37 ± 0.74 |
Clinical parameters at baseline as related to jaw (maxilla/mandible), tooth type (anterior/premolar), and site (interproximal/buccal and oral) (mean ± standard deviation)
| Maxilla | mandible | premolar | anterior | interproximal | buccal/oral | |
|---|---|---|---|---|---|---|
| Sites | 1,926 | 2,220 | 1,590 | 2,566 | 2,764 | 1,382 |
| RAL-V/mm | 5.24 ± 2.14* | 5.00 ± 2.26 | 5.19 ± 2.20* | 5.07 ± 2.22 | 5.37 ± 2.26* | 4.60 ± 2.01 |
| PPD/mm | 3.55 ± 1.88* | 3.00 ± 1.78 | 3.47 ± 1.88* | 3.12 ± 1.81 | 3.67 ± 1.82* | 2.43 ± 1.59 |
| GI | 0.80 ± 0.98* | 0.76 ± 0.96 | 0.83 ± 0.97* | 0.75 ± 0.96 | 0.89 ± 0.98* | 0.56 ± 0.89 |
| PlI | 0.11 ± 0.43* | 0.19 ± 0.57 | 0.14 ± 0.48* | 0.17 ± 0.53 | 0.18 ± 0.54* | 0.11 ± 0.44 |
*Statistically significantly different with p < 0.001
Clinical parameters at 3 and 6 months after therapy as related to therapy (mean ± standard deviation)
| 3 months after therapy | 6 months after therapy | |||||
|---|---|---|---|---|---|---|
| No therapy | SRP | AF | No therapy | SRP | AF | |
| Sites | 1,440 | 2,478 | 198 | 1,440 | 2,478 | 198 |
| RAL-V (mm) | 4.37 ± 1.76 | 5.13 ± 1.90 | 5.14 ± 1.64 | 4.47 ± 1.76 | 5.17 ± 1.85 | 5.11 ± 1.61 |
| PPD (mm) | 2.33 ± 0.96 | 2.84 ± 1.25 | 3.09 ± 1.34 | 2.35 ± 1.05 | 2.83 ± 1.24 | 2.99 ± 1.27 |
| GI | 0.36 ± 0.76 | 0.58 ± 0.90 | 0.69 ± 0.94 | 0.36 ± 0.76 | 0.58 ± 0.90 | 0.65 ± 0.93 |
| PlI | 0.22 ± 0.56 | 0.36 ± 0.74 | 0.52 ± 0.89 | 0.31 ± 0.68 | 0.41 ± 0.78 | 0.27 ± 0.65 |
SRP Scaling and root planing, AF access flap
Change of clinical parameters at 3 and 6 months after therapy as related to therapy (mean ± standard deviation)
| 3 months after therapy | 6 months after therapy | |||||
|---|---|---|---|---|---|---|
| No therapy | SRP | AF | No therapy | SRP | AF | |
| Sites | 1,440 | 2,478 | 198 | 1,440 | 2,478 | 198 |
| RAL-V (mm) | 0.03 ± 0.74 | 0.41 ± 1.11* | 0.26 ± 1.06* | 0.12 ± 0.94 | 0.38 ± 1.20* | 0.28 ± 1.18* |
| PPD (mm) | −0.11 ± 0.72 | −0.82 ± 1.33* | −0.89 ± 1.25* | 0.09 ± 0.87 | −0.82 ± 1.40* | −0.99 ± 1.41* |
| GI | −0.13 ± 0.97 | −0.36 ± 1.14* | −0.33 ± 1.14* | −0.13 ± 1.03 | −0.36 ± 1.18* | −0.36 ± 1.44* |
| PlI | 0.08 ± 0.69 | 0.20 ± 0.82* | 0.37 ± 0.97* | 0.16 ± 0.75 | 0.25 ± 0.87* | 0.13 ± 0.68* |
SRP Scaling and root planing, AF access flap
*Statistically significantly different from no therapy with p < 0.001
Backward multilevel linear regression analysis—dependent variable: RAL-V reduction 6 months after therapy, n = 40 patients, 4,146 sites
| Estimate | SE | ||||
|---|---|---|---|---|---|
| Intercept | −1.8776 | 0.1068 | 37 | ||
| Current smoking | −0.2875 | 0.1106 | 3,427 | 6.76 | 0.0094 |
| Site (interproximal) | −0.2341 | 0.0277 | 3,427 | 71.28 | <0.0001 |
| Aggressive periodontitis | −0.2903 | 0.1308 | 3,427 | 4.93 | 0.0265 |
| Baseline PPD | 0.2746 | 0.0158 | 3,427 | 303.72 | <0.0001 |
| Baseline RAL-V | 0.1832 | 0.0141 | 3,427 | 169.61 | <0.0001 |
Backward multilevel linear regression analysis—dependent variable: PPD reduction 6 months after therapy, n = 40 patients, 4,146 sites
| Estimate | SE | ||||
|---|---|---|---|---|---|
| Intercept | −1.6487 | 0.1037 | 38 | ||
| Current smoking | −0.3312 | 0.1055 | 3,451 | 9.86 | 0.0017 |
| Jaw (maxilla) | −0.1299 | 0.0324 | 3,451 | 16.05 | <0.0001 |
| Site (interproximal) | −0.3664 | 0.0262 | 3,451 | 195.10 | <0.0001 |
| Tooth type (premolar) | −0.0501 | 0.0338 | 3,451 | 2.20 | 0.1381 |
| Baseline PPD | 0.6162 | 0.0146 | 3,451 | 1774.31 | <0.0001 |
| Baseline RAL-V | −0.0354 | 0.0128 | 3,451 | 7.63 | 0.0058 |
| Baseline Plaque Index | −0.0368 | 0.0244 | 3,451 | 2.27 | 0.1318 |
| Scaling and root planing | 0.1171 | 0.0392 | 3,451 | 4.48 | 0.0114 |
| Access flap | 0.0997 | 0.0861 | 3,451 | 4.48 | 0.0114 |
Multilevel linear regression analysis—dependent variable: RAL-V reduction 6 months after therapy, n = 36 patients, 1,796 sites
| Estimate | SE | ||||
|---|---|---|---|---|---|
| Intercept | −1.8290 | 0.1385 | 33 | ||
| Current smoking | −0.3758 | 0.1334 | 1,313 | 7.94 | 0.0049 |
| Tooth type (premolar) | −0.0763 | 0.0502 | 1,313 | 2.31 | 0.1292 |
| Aggressive periodontitis | −0.3311 | 0.1635 | 1,313 | 4.10 | 0.0431 |
| Baseline PPD | 0.2371 | 0.0256 | 1,313 | 85.86 | <0.0001 |
| Baseline RAL-V | 0.2637 | 0.0242 | 1,313 | 118.36 | <0.0001 |
| Bone loss in % | −0.0115 | 0.0016 | 1,313 | 50.58 | <0.0001 |
Multilevel linear regression analysis—dependent variable: PPD reduction 6 months after therapy, n = 36 patients, 1,796 sites
| Estimate | SE | ||||
|---|---|---|---|---|---|
| Intercept | −2.0771 | 0.1364 | 34 | ||
| Current smoking | −0.4646 | 0.1197 | 1,313 | 15.08 | 0.0001 |
| Jaw (maxilla) | −0.1469 | 0.0433 | 1,313 | 11.51 | 0.0007 |
| Baseline PPD | 0.6286 | 0.0119 | 1,313 | 2791.95 | <0.0001 |
| Baseline Plaque Index | −0.0550 | 0.0332 | 1,313 | 2.75 | 0.0097 |
| Infrabony defect | −0.2932 | 0.0671 | 1,313 | 19.10 | <0.0001 |